Ozanimod Is an Efficacious Oral Therapy After 5-ASA Failure in Immunomodulator- and Biologic-Naive Patients With Ulcerative Colitis: Post Hoc Analysis From True North.
出版信息
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):4-5.
Abstract
摘要
相似文献
1
2
Post Hoc Analyses of the True North Study Evaluating Ozanimod in Patients with Ulcerative Colitis.评估奥扎莫德治疗溃疡性结肠炎患者的“北极星研究”的事后分析
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):3-4.
3
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.奥扎莫德用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
4
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
5
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD000543. doi: 10.1002/14651858.CD000543.pub4.
6
Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.奥扎莫德：治疗溃疡性结肠炎的鞘氨醇 1-磷酸受体调节剂中的首创药物。
Ann Pharmacother. 2022 May;56(5):592-599. doi: 10.1177/10600280211041907. Epub 2021 Aug 22.
7
An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.奥扎莫德作为一种治疗成人中重度活动性溃疡性结肠炎的治疗选择的概述。
Expert Opin Pharmacother. 2022 Jun;23(8):893-904. doi: 10.1080/14656566.2022.2071605. Epub 2022 May 9.
8
Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.在开始使用生物疗法的溃疡性结肠炎患者中停用 5-氨基水杨酸不会增加不良临床结局的风险：两项全国性基于人群队列的分析。
Gut. 2019 Jun;68(6):977-984. doi: 10.1136/gutjnl-2018-317021. Epub 2018 Nov 12.
9
Update on ozanimod for ulcerative colitis.溃疡性结肠炎奥扎莫德更新。
Drugs Today (Barc). 2022 Jul;58(7):351-367. doi: 10.1358/dot.2022.58.7.3408818.
10
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.口服5-氨基水杨酸用于维持溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3.
引用本文的文献
1
Post Hoc Analyses of the True North Study Evaluating Ozanimod in Patients with Ulcerative Colitis.评估奥扎莫德治疗溃疡性结肠炎患者的“北极星研究”的事后分析
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):3-4.
2
Highlights in Ulcerative Colitis From the ACG Annual Scientific Meeting: Commentary.美国胃肠病学会年会溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):13-16.
3
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease.沙特阿拉伯成人炎症性肠病诊断与管理共识指南。
Saudi J Gastroenterol. 2022 Nov 21;29(Suppl 1):S1-S35. doi: 10.4103/sjg.sjg_277_22.
4
Ozanimod: A Review in Ulcerative Colitis.奥扎莫德：溃疡性结肠炎的研究进展。
Drugs. 2022 Aug;82(12):1303-1313. doi: 10.1007/s40265-022-01762-8. Epub 2022 Aug 22.
5
Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.欧洲克罗恩病和结肠炎组织第17届大会溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):13-16.
本文引用的文献
1
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.奥扎莫德用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
Zotero 插件